Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study.
Izumi N, Asahina Y, Kurosaki M, Yamada G, Kawai T, Kajiwara E, Okamura Y, Takeuchi T, Yokosuka O, Kariyama K, Toyoda J, Inao M, Tanaka E, Moriwaki H, Adachi H, Katsushima S, Kudo M, Takaguchi K, Hiasa Y, Chayama K, Yatsuhashi H, Oketani M, Kumada H. Izumi N, et al. Among authors: inao m. J Gastroenterol. 2013 Mar;48(3):382-90. doi: 10.1007/s00535-012-0641-9. Epub 2012 Aug 9. J Gastroenterol. 2013. PMID: 22875473 Free PMC article.
Randomized study comparing vitamin D3 and 1α-Hydroxyvitamin D3 in combination with pegylated interferon/ribavirin therapy for chronic hepatitis C.
Omori-Mizuno Y, Nakayama N, Inao M, Funyu J, Asabe S, Tomita K, Nishikawa K, Hosoda Y, Tanaka M, Hashimoto Y, Yakabi K, Koshima Y, Mochida S. Omori-Mizuno Y, et al. Among authors: inao m. J Gastroenterol Hepatol. 2015 Sep;30(9):1384-90. doi: 10.1111/jgh.12949. J Gastroenterol Hepatol. 2015. PMID: 25778685 Clinical Trial.
Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing.
Uchida Y, Kouyama J, Naiki K, Sugawara K, Ando S, Nakao M, Motoya D, Inao M, Imai Y, Nakayama N, Mochida S. Uchida Y, et al. Among authors: inao m. J Gastroenterol. 2016 Mar;51(3):260-70. doi: 10.1007/s00535-015-1106-8. Epub 2015 Aug 6. J Gastroenterol. 2016. PMID: 26245700
Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy.
Uchida Y, Naiki K, Kouyama JI, Sugawara K, Nakao M, Motoya D, Inao M, Nakayama N, Imai Y, Tomiya T, Mochida S. Uchida Y, et al. Among authors: inao m. PLoS One. 2018 Oct 11;13(10):e0205600. doi: 10.1371/journal.pone.0205600. eCollection 2018. PLoS One. 2018. PMID: 30308053 Free PMC article. Clinical Trial.
Retreatment with sofosbuvir/ledipasvir with or without lead-in interferon-β injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapy.
Uemura H, Uchida Y, Kouyama JI, Naiki K, Yamaba S, Fuchigami A, Saito Y, Shiokawa K, Fujii Y, Uchiya H, Nakazawa M, Ando S, Nakao M, Motoya D, Sugawara K, Inao M, Imai Y, Nakayama N, Tomiya T, Mochida S. Uemura H, et al. Among authors: inao m. Hepatol Res. 2018 Mar;48(4):233-243. doi: 10.1111/hepr.12980. Epub 2017 Oct 20. Hepatol Res. 2018. PMID: 28884930
59 results